IM4TB Overview
- Founded
-
2013
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$769K
- Investors
-
2
IM4TB General Information
Description
Developer of faster-acting medicines designed to fight all forms of tuberculosis. The company's drug allows the treatment duration to be shortened and substantially diminishes the risks of failure of treatment, relapse of the disease, and increased prevalence of drug-resistance bacteria, enabling clinicians to provide a cure for tuberculosis disease in a pain-free way.
Contact Information
Website
www.im4tb.org
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- EPFL Innovation Park
- Building I
- 1015 Lausanne
- Switzerland
+41 021 000 00 00
IM4TB Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 01-Sep-2022 | $769K | Completed | Generating Revenue | ||
| 2. Grant | 16-Mar-2015 | 00000 | Completed | Startup | ||
| 1. Accelerator/Incubator | Completed | Startup |
IM4TB Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Iain Old Ph.D | Operational Director |
IM4TB Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Gabriel Clerc | Self | Vice Chairman of the Board | 000 0000 |
| Laurent Fraisse Ph.D | Self | Board Member | 000 0000 |
| Laurent Nicod MD | Self | Board Member | 000 0000 |
| Stewart Cole | Self | Chairman of the Board | 000 0000 |
| Thierry Buclin | Self | Board Member | 000 0000 |
IM4TB Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | 000 0000 | 000000 0 | ||
| EPFL Innovation Park | Accelerator/Incubator | 000 0000 | 000000 0 |